DALLAS, June 9, 2015 /PRNewswire/ --
Market research reports titled Global Heparin Sodium Industry Report 2015, China Heparin Industry Report, 2014-2017 and China Heparin Sodium Industry Report 2015 are now available with ReportsnReports.com.
Complete report on global heparin sodium market spread across 136 pages, analyzing about 12 major global and regional companies as well as supported with 188 tables and figures is now available at http://www.reportsnreports.com/reports/401780-global-heparin-sodium-industry-report-2015.html .
The Global Heparin Sodium Industry Report 2015 is a professional and in-depth study on the current state of the Heparin Sodium market. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Heparin Sodium market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.
Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This heparin sodium market report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Heparin Sodium industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.
With tables and figures on heparin sodium market that provide key statistics on the state of the global industry, this research is a valuable source of guidance and direction for companies and individuals interested in the heparin sodium market. Companies profiled in this research report include Sandoz, Opocrin, Pfizer, SPL, Shenzhen Hepalink, Nanjing King-friend, Changzhou Qianhong, Dongcheng Biochemicals, Dongying Tiandong, Changshan Biochemical, Nanjing Xinbai and Sichuan Deebio. Order a copy of global heparin sodium market 2015 research report at http://www.reportsnreports.com/Purchase.aspx?name=401780 .
The second research on China Heparin Industry Report, 2014-2017 says The major global heparin API suppliers, including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma, and Changshan Biochemical Pharmaceutical, have been among the top 4 heparin exporters in China for many years, together accounting for over 60% of China's total heparin exports. In response to the impact from international markets, enterprises are stepping up efforts to figure out the solutions, with Hepalink expanding its market share of heparin crude products via M&As overseas. By contrast, the enterprises like Qianhong Bio-pharma, Dongcheng Biochemicals, and Changshan Biochemical Pharmaceutical have accelerated the R&D into and production of low molecular weight heparin preparations. And Nanjing King-friend is aggressively seeking to expand capacity through IPO.
Although the leading heparin enterprises planned to increase capacity and improve the heparin industry chain a few years ago, yet quite a few heparin API projects that had been scheduled to go into operation in 2014 were delayed successively due to depressed market demand or improved technical standards, these projects including Dongcheng Biochemicals' 32t/a Crude Heparin Sodium Project and Qianhong Bio-pharma's Heparin API and Preparations Expansion Project.
In terms of the proposed/ongoing projects, however, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China's total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand. Given that America's economy showed signs of recovery and the European economy did not continue to deteriorate, we foresee that the market size of the global heparin API and preparation market will bounce back in 2014-2017, when China's heparin industry, heparin API in particular, will see an improved degree of prosperity, thus further releasing new capacity.
Key heparin market enterprises of China profiled and analyzed in this research report include Hepalink, Qianhong Bio-pharma, Dongcheng Biochemicals, Changshan Biochemical Pharmaceutical, Tianjin Chase Sun Pharmaceutical, Nanjing King-friend and Wanbang Biopharmaceuticals. Order a copy of China Heparin Industry Report, 2014-2017 at http://www.reportsnreports.com/Purchase.aspx?name=312048 .
On a related note, ReportsnReports.com also offers China Heparin Sodium Industry Report 2015 on the Chinese heparin sodium market with forecasts to 2020 on capacity and production overview, production market share by product type of heparin sodium, sales and sales revenue overview, china sales of heparin sodium by applications, import, export and consumption as well as import, export and consumption. Companies like Sichuan Deebio, Nanjing Xinbai, Changshan Biochemical, Dongying Tiandong, Dongcheng Biochemicals, Changzhou Qianhong, Nanjing King-friend, Shenzhen Hepalink, SPL, Pfizer, Opocrin and Sandoz are profiled in this research on Chinese heparin sodium market available at http://www.reportsnreports.com/reports/401815-china-heparin-sodium-industry-report-2015.html .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+/Google Plus: https://plus.google.com/111656568937629536321/posts
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252